PF-08032560

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NamePF-08032560
Drug Alias NamePF-08032560
ClassificationBiologics
Mechanisms of ActionHistone acetyltransferase KAT7 inhibitorsHistone acetyltransferase KAT6A inhibitorsHistone acetyltransferase KAT6B inhibitors
TargetsHistone acetyltransferase KAT6AHistone acetyltransferase KAT7Histone acetyltransferase KAT6B
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A